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WE previously demonstrated that Bothrops jararaca
venom  (BjV)  has  an  antitumor  effect  on  Ehrlich
ascites tumor (EAT) cells and induces an increase of
polymorphonuclear  leukocytes  in  early  stages  of
tumor growth. It has been reported that this venom
presents  an  important  inflammatory  effect  when
inoculated in animal  models  and in human snake-
bites, and that cytokine levels have been detected in
these cases. To evaluate whether the cytokines can be
involved with the suppression of the tumoral growth,
we  evaluate  the  cytokine  profile  in  the  peritoneal
cavity of mice inoculated with EAT cells and treated
with BjV. Swiss mice were inoculated with EAT cells
by  the  intraperitoneal  route  and  treated  with  BjV
venom (0.4mg/kg, intraperitoneally), on the 1st, 4th,
7th,  10th,  and  13th  day.  Mice  were  evaluated  for
cytokine levels on the 2nd, 5th, 8th, 11th and 14th
day. Analysis was performed using an enzyme-linked
immunosorbent assay for interleukin (IL)-1a , IL-2, IL-
4, IL-6, IL-10, IL-13, and tumor necrosis factor-a (TNF-
a )  levels  in  the  peritoneal  washing  supernatant.
Results  were  analyzed  statistically  by  the  Kruskal–
Wallis and Dunn’s tests at the 5% level of significance.
We  observed  that  EAT  implantation  induces  IL–6
production  on  the  11th  and  14th  days  of  tumor
growth, IL-10 on the 11th day and TNF-a on the 14th
day. The treatment with BjV suppresses production of
these cytokines. In addition, IL–13 was produced by
animals that were inoculated only with venom on the
11th and 14th days, and by the group inoculated with
EAT cells and treated with venom on the 2nd and 14th
days. Furthermore, we suggest that the IL–6 detected
in the present study is produced by the EAT cells and
the suppression of its production could be associated
with the antitumor effect of BjV.
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Introduction
We previously demonstrated that Bothrops jararaca
venom  (BjV)  has  an  antitumor  effect  on  Ehrlich
ascites tumor (EAT) cells.1 Other experimental studies
have been performed using snake venoms for treating
animal tumors, and we observed that there are still
many  controversies  on  this  subject  and  that  the
mechanism  of  tumor  growth  inhibition  was  not
clear.2
Inflammation  induced  by  snake  venoms,  with
inflammatory  cell  involvement  and  cytokine  libera-
tion, was suggested as an important factor in tumor
growth inhibition.2 Elevated levels of some cytokines
in  human  accidents  with  venomous  animals3 and
experimental studies4,5 have been demonstrated.
Literature  on  neoplasias  and  cytokines  is  quite
extensive, and its approach in the in vivo models is
very complex. Several reports have demonstrated that
snake  venoms  may  induce  increased  serum  levels
of  interferon  alpha  (INFa),  tumor  necrosis factor-a
(TNF-a), interleukin (IL)-1, IL-6, IL-8, and IL-10.3–5
It has also been demonstrated that certain snake
venoms show a proteolytic effect on cytokines. In this
sense, it is already known that Crotalus atrox venom
degrades  interferon  and  IL-2.6 In  addition  to  the
proteolytic  effect,  the  literature  also  describes  an
inhibitory  effect  in  cytokine production  by  certain
snake venoms.7,8
There are other reports that demonstrate an asso-
ciation between cytokines and tumor growth inhibi-
tion. The main cytokines involved in this response are
TNF-a,9,10,  IL-1a,11,12 IL-2,13 IL-4,14,15 IL-6,16,17 IL-
1018,19 and  IL-13.20,21 These  cytokines  can  act  as
inhibitory  substances  or  growth  factors  for  tumor
cells.
In our previous report on this subject, we demon-
strated that the in vivo treatment of mice bearing EAT
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106 EAT cells/ml versus 0.7 ´ 106 EAT cells/ml, on the
14th  day),  increased  animal  survival  time  (15.5%
versus  64.3%),  and  induced  an  increase  of  poly-
morphonuclear  leukocytes  in  early  stages of tumor
growth (2nd and 5th days), but the total number of
mononuclear leukocytes was not affected.1 We sug-
gest that the antitumor effect of BjV1,2,22 is due to the
direct action of some substance of the venom, mainly
proteases, but  could  also be by  an indirect action,
through  stimulation  of  the  inflammatory  reaction,
with involvement of cells and cytokines. To evaluate
whether  the  cytokines  can  be  involved  with  the
suppression of the tumoral growth, we evaluate the
cytokine  profile  in  the  peritoneal  cavity  of  mice
inoculated with EAT cells and treated with BjV.
Materials and methods
Animals
Swiss strain male mice, 4–6 weeks old, from our own
animal  facilities  were  used  throughout  the
experiment.
Venoms
BjV was obtained from snakes maintained in captivity
at The Center for the Study of Venoms and Venomous
Animals of S˜ ao Paulo State University, Brazil. Newly
extracted  venom  was  centrifuged  for  10min  at
1500rpm, filtered using a GSWP00250 Millipore filter
and then lyophilized. The lethal dose 50 (LD50) for
this venom was previously determined as 2.4mg/kg
of animal weight. The venom was stored at 4(C during
the experiment.
Ehrlich ascites tumor
The tumor was maintained in Swiss mice in the ascitic
form. Tumor cells were collected by aspiration with a
Pasteur pipette, centrifuged for 10min at 200g, and
washed  twice  with  phosphate-buffered  saline  (pH
7.2). In all experimental protocols, mice were injec-
ted intraperitoneally with 1 ´ 103 tumor cells. Cell
viability was evaluated by trypan blue exclusion test,
and only cell suspensions that presented more than
95% viability were used.
Experimental design (Fig. 1)
Four groups of 25 animals were formed: G1, saline
control group; G2, venom control group (0.4mg/kg);
G3, EAT control group; and G4, EAT + 0.4mg/kg of
venom. Animals of groups G3 and G4 were inoculated
with 1 ´ 103 tumor cells/ml into the peritoneal cavity.
Treatment began 24h after tumor cell inoculation and
consisted  of  five  intraperitoneal  injections  at  72–h
intervals between each. The saline (G1)  and tumor
(G3) control groups were injected with saline solu-
tion,  and  the  venom  control  group  (G2)  and  the
venom + EAT group (G4) were inoculated with BjV
(0.4mg/kg). On the 2nd, 5th, 8th, 11th, and 14th days
after inoculation, five animals from each group were
sacrificed in a sulfur ether chamber. After abdominal
region asepsis, each mouse was inoculated with 3ml
of saline. After homogenization, the solution contain-
ing peritoneal cells was removed and centrifuged, and
the  supernatant was  stored at –20°C. These proce-
dures were repeated twice and data were grouped for
statistical analysis.
Immunoenzymatic assay
The  cytokine  profile  was  obtained  through  immu-
noenzymatic  assay  (enzyme-linked  immunosorbent
assay)  using  supernatant  aliquots  of  the  peritoneal
washing. The following cytokines were analyzed: TNF-
a, IL-1a, IL-2, IL-4, IL-6, IL-10 and IL-13. The protocols,
antibodies and reagents employed were as  per  the
manufacturer’s recommendations (R&D Systems Inc.,
Minneapolis, USA).
Statistical analysis
The data were analyzed by the Kruskal–Wallis non-
parametric test for independent samples. The differ-
ences  between  the  groups  were  appraised  by  the
Dunn’s method. The significance level was 5%.
Results
There were no significant differences observed in IL-
1a and IL-2 production to any group throughout the
study. However, IL-1a was slightly  increased on the
2nd and 5th days for the group inoculated with EAT
cells and treated with venom, and IL-2 on the 8th day
for the group inoculated only with BjV (Table 1). IL-4
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FIG. 1. Experimental design for evaluation of the cytokine
profile of mice inoculated intraperitoneally (IP) with EAT cells
and  treated  with  BjV  (0.4mg/kg).  ELISA,  Enzyme-linked
immunosorbent assay.levels  were  not  detected  in  all  groups  (data  not
shown).
Results for IL-6 production are shown in Fig. 2. The
group  inoculated  with  EAT  cells  and  treated  with
saline (G3) presented significantly higher IL-6 levels
on the 11th and 14th days in relation to the saline
control group  (G1).  On  the  contrary,  in  the  group
inoculated with EAT cells and treated with BjV (G4),
this exponential increase of IL-6 was not observed. IL-
6 levels was also observed in the group treated just
with  venom  (G2)  in  relation  to  the  saline  control
group (G1) on the 5th day.
The IL-10 analysis showed a significant increase of
its level on the 11th day in the group inoculated with
EAT and treated with saline (G3)  in relation to the
saline control group (G1) (Fig. 3).
For IL-13, analysis showed no significant increase in
the group inoculated with EAT and treated with saline
(G3).  On  the  contrary,  significant  increases of  this
cytokine were seen in the EAT and BjV group (G4) on
the 2nd and 14th days in relation to the control group
(G1). On the 14th day, IL-13 increase in the venom
control  group  (G2)  was  also  significant  compared
with the EAT and saline group (G3) (Fig. 4).
TNF-a production analysis showed that the group
inoculate with EAT cells and treated with saline (G3)
presented significantly higher levels on the 14th day
than the two non-inoculated groups treated (G2) or
not treated (G1) with BjV (Fig. 5).
Discussion
The present study was performed because we were
interested in determining whether some cytokine was
involved in the process of inhibition of the growth
tumoral  after  treatment  with  BjV,  as  previously
demonstrated.1
The analysis of cytokines in the peritoneal cavity
showed that, in the EAT group, TNF-a, IL-6, IL-10 were
produced in later stages of tumor growth (11th and/
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Table 1. Cytokine levels in the experimental groups inoculated with EAT cells and/or 0.4mg/kg of BjV after 2, 5, 8, 11, and 14
days of tumor growth
Time Day Cytokine levels (pg/ml) in the groups
Saline 0.4mg/kg BjV EAT EAT + 0.4mg/kg BjV
IL-1 2 3.6 (6.5)* 2.3 (2.1) 2.8 (2.4) 9.0 (11.8)
5 3.7 (5.7) 4.5 (8.5) 3.3 (6.1) 8.6 (15.1)
8 0.2 (8.5) 5.7 (5.0) 2.3 (3.4) 3.3 (4.9)
11 0.8 (3.6) 1.8 (1.2) 1.6 (5.5) 4.2 (3.4)
14 0.0 (0.2) 1.3 (1.6) 1.3 (2.6) 0.8 (1.6)
IL-2 2 0.0 (0.0) 0.0 (0.0) 0.0 (0.0) 0.0 (1.1)
5 0.0 (0.4) 0.0 (3.9) 0.0 (5.4) 1.5 (5.4)
8 3.2 (3.9) 15.5 (11.1) 0.4 (8.9) 3.6 (3.2)
11 0.0 (18.0) 0.0 (0.0) 0.0 (0.0) 0.0 (1.1)
14 0.0 (0.0) 0.0 (5.4) 0.0 (3.2) 0.0 (5.4)
* Each value represent the median (semi-interquartile range) for the cytokine level.
FIG. 2. Box plot of the IL-6 level kinetics in EAT cells treated
with  BjV.  Each  box  represents  25–75%  values  with  the
median as an internal line, the error bar represents 10% and
90%, and the circle  represents the outliers. Statistics: 2nd
day, G4 > (G1 = G2 = G3); 5th day, G2 > G1; 11th day, G3 > (G1
= G4); 14th day, G3 > (G1 = G2 = G4); p < 0.05.
FIG. 3. Box plot of the IL-10 level kinetics in EAT cells treated
with  BjV.  Each  box  represents  25–75%  values  with  the
median as an internal line, the error bar represents 10% and
90%, and the circle represents the outliers. Statistics: 11th
day, G3 > G1; p < 0.05.or 14th day). IL-13 levels was detected mainly in the
groups treated with BjV, independently of the pres-
ence of EAT cells. IL-1 and IL-2 levels were very low
when compared with those obtained for TNF-a, IL-6,
IL-10 and IL-13. However, the most important cyto-
kine detected in our protocols was IL-6. After treat-
ment of EAT cells with BjV, the production of TNF-a,
IL-6, and IL-10 was suppressed.
There were no significant increases between EAT
groups for IL-1a, IL-2, IL-4, and IL-13 throughout the
experiment. However, we observed a slight tendency
for increased IL-1a levels in the beginning stages of
the  experiment,  in  IL-2  levels  on  day  8  of  tumor
growth, and  in  IL-13  during  the final  stages of the
experiment. Although these slight increases are not
significant, these cytokines may also be involved in
tumor growth inhibition.
Although we did not observe increased IL-4 levels,
the structure of L-amino acid oxidase, a very common
enzyme  in  snake  venoms,  shows a  high  degree  of
homology  with  murine  IL-423 and  therefore  it  is
possible that this enzyme present in BjV24,25 exerts an
antitumor  effect  on  the  EAT  cells  similar  to  that
obtained with IL-4 treatment.14,15There are reports in
the  literature  that  show  the  direct  toxic  effect  of
L-amino acid oxidase Ophiophagus hannah on stom-
ach  cancer  cells,  murine  melanoma,  fibrosarcoma,
and colorectal cancer.26
In addition to these studied cytokines, it is impor-
tant to remember that, in the in vivo model, other
cytokines may be playing a role in the effect observed
after treatment. It is possible that the antitumor effect
on EAT treated with BjV is associated with the action
of  other cytokines possessing antitumor properties,
such as IL-12.27 However, it is also possible that the
EAT produce other cytokines promoting its growth;
for instance, transforming growth factor-b.28
In the present study, comparing cytokine levels in
the animals treated only with venom, we observed a
significant increase in IL-6 on the 5th day, and IL-13 on
the 11th and 14th days in relation to the saline control
group. Also, although not statistically significant, we
detected an increase in TNF-a and IL-2 on the 8th day
and in IL-4 and IL-10 from day 11. These data suggest
that treatment with BjV induces a TH2 behavior in the
cytokine profile during the end stages of  the study
period, as reported for the Crotalus durissus terrifi-
cus venom.7
After  analyzing  the  literature,  we  can  infer  that
there is a close relationship between snake venoms,
cytokines, and tumor cells. However, the literature on
this subject is controversial and shows that treatment
of tumors with snake venoms may or may not induce
an  anti-neoplastic effect2 and  that, in  certain situa-
tions,  snake venoms  induce  cytokine  release;3–5 in
others, they either did not induce7,8 or degraded6 the
produced cytokines. For some cytokines evaluated in
this study,  an antitumor effect13,19 or that they are
used as growth factors by  tumor cells9,18 has been
reported.
The  results  observed  in  our  previous  paper,  in
which we reported inhibition  of  EAT  cell  growth1,
associated with  modulation  of  the  cytokine profile
observed in the present paper, mainly for TNF-a, IL-6,
and IL-10 production, suggest a effective inter-relation
among cytokines and inhibition of EAT cell growth.
Since  IL-6  was  produced  in  significantly  higher
quantities than TNF-a and IL-10, we believe that IL-6 is
the main cytokine associated with EAT growth, either
as a growth  factor or  a  host suppressor factor. We
suggest that tumor growth inhibition was largely due
to the suppression of IL-6 production and that this
suppression may be associated in part with proteol-
ysis induced by BjV.
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FIG. 4. Box plot of the IL-13 level kinetics in EAT cells treated
with  BjV.  Each  box  represents  25–75%  values  with  the
median as an internal line, the error bar represents 10% and
90%, and the circle  represents the outliers. Statistics: 2nd
day, G4 > G1; 11th day, G2 > G1; 14th day, G2 > (G1 = G3), G4
> G1; p < 0.05.
FIG. 5. Box plot of the TNF-a level kinetics in EAT cells treated
with  BjV.  Each  box  represents  25–75%  values  with  the
median as an internal line, the error bar represents 10% and
90%, and the circle represents the outliers. Statistics: 14th
day, G3 > (G1 = G2); p < 0.05.Comparing  the  results  obtained for  the  cytokine
levels with those obtained for the tumoral growth,1
we can note a correlation between the increase in
TNF-a, IL-6 and IL-10 levels and the tumor growth in
the  non-venom  EAT  group,  which  was  the  group
where a high rate of tumor growth was observed. On
the contrary, no significant levels of these cytokines
was observed in EAT groups that were treated with
BjV. In our previous observation, in this latter group,
the tumor growth was inhibited.1We can suggest that
the tumor cells are producing or inducing production
of  these  cytokines. These  results  are  in  agreement
with the literature on the production of TNF-a
9,10 and
IL-616,17 by  tumor  cells  and  also  induction  of  IL-
1018 by cells of the host, the latter stimulating tumor
growth.
Although the treatment of mice bearing EAT cells
with BjV did not induce a significant difference in the
total number of mononuclear leukocytes,1 we do not
rule out the possibility that different subpopulations
may be involved in tumor growth inhibition. At the
moment, we are evaluating through flow cytometry
which populations of mononuclear cells are involved
in the response of inhibition of the tumor growth, so
that  we  will  better  be  able  to  understand  the
relationships among the tumor evolution, the inflam-
matory  influx,  and  the  cytokine  profile  in  mice
bearing EAT cells treated with BjV.
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